For education only · Not medical advice
← All articles
September 2026 Hormone Health 7 min read

Sermorelin: the oldest GHRH analogue, and what happened to it

Sermorelin is one of the few grey-market peptides that was once a properly approved drug, which makes it an unusually clear case study in how a molecule can be real, well understood, and still unproven for the thing people buy it for.

The short answer

  • Sermorelin is the first 29 amino acids of human growth hormone releasing hormone (GHRH), and it works exactly the way GHRH does: it tells the pituitary to release a pulse of growth hormone.
  • It was approved twice in the United States, as Geref Diagnostic for pituitary testing (approved 28 December 1990) and as Geref for idiopathic growth hormone deficiency in children (approved 26 September 1997). The manufacturer discontinued both in 2008, and FDA withdrew approval effective 18 June 2009.
  • Evidence tier, split by use: Human trials (historically Approved) for paediatric growth hormone deficiency and for pituitary diagnostic testing. Preclinical only for the adult body composition and anti-aging uses it is actually sold for, where no adequately powered randomised trial with clinical endpoints exists.
  • Its plasma half-life is roughly 4 minutes. It produces one brief growth hormone pulse per injection and cannot produce sustained elevated growth hormone.
  • As of September 2026 there is no marketed sermorelin product in the United States or Canada, and it is prohibited at all times under WADA’s 2026 Prohibited List, section S2.2.4.

What sermorelin actually is

Endogenous GHRH is a 44 amino acid peptide made in the hypothalamus. Its first 29 residues carry essentially all of the receptor activity, which is why the whole GHRH analogue class is built on that fragment. Sermorelin is that fragment, amidated at one end, about 3358 Da.

It is a full agonist at the GHRH receptor on pituitary somatotrophs. Binding raises cAMP, activates protein kinase A, and triggers both the release of stored growth hormone and fresh transcription of the growth hormone gene. That is the entire mechanism. Sermorelin has no meaningful activity at the ghrelin receptor, does not raise cortisol or prolactin the way some growth hormone releasing peptides do, and has no known tissue repair action of its own. Claims that it repairs tissue directly are unsupported; any downstream effect runs through growth hormone and IGF-1.

Three consequences follow, and all three are demonstrated in humans.

It needs a working pituitary. In people with structural pituitary damage the growth hormone response is absent or blunted. That is precisely why the low-dose ampoule was approved as a diagnostic agent: it separates hypothalamic from pituitary causes of deficiency.

It stays inside the feedback loop. Growth hormone released under GHRH stimulation is still subject to somatostatin tone and to feedback from growth hormone and IGF-1, so sermorelin amplifies pulses that already exist rather than creating a continuous plateau. That is the honest basis of the claim that secretagogues are more physiological than injected growth hormone, and it is a claim about mechanism rather than outcomes.

The regulatory history matters more than it looks

Geref and Geref Diagnostic were not pulled for danger. The manufacturer discontinued production in 2008 and asked for both applications to be withdrawn, and FDA formally determined in 2013 that the products were not withdrawn for reasons of safety or effectiveness. That distinction is load-bearing: a withdrawal on safety or efficacy grounds would place a substance on FDA’s withdrawn-or-removed list and bar it from compounding. A commercial discontinuation does not.

What sermorelin does not have is a documented place in the US compounding framework. It appears in none of the three categories of FDA’s 503A nominations list as updated 14 May 2026, and there is no USP or NF monograph for sermorelin acetate. Compounders widely treat it as eligible on the theory that it is a component of a formerly approved drug product, but FDA has not confirmed that reading in writing, so “sermorelin is legal to compound” is an industry position rather than an agency determination.

In Canada the position as of September 2026 is simpler. There is no sermorelin entry in the Drug Product Database, so no DIN and no Canadian label. Sermorelin was among the unauthorized injectable peptides named in Health Canada’s 1 August 2025 Canada Peptide advisory, and its public advisory of 9 April 2026 states that peptides are generally regulated as prescription drugs in Canada, that unauthorized products are unassessed for safety, efficacy and quality, and that a “research use only” label confers no legal status of its own.

What the human evidence covers, and what it does not

The regulatory-grade data cover two things: telling whether a pituitary can release growth hormone, and increasing height velocity in children with idiopathic growth hormone deficiency. Both were supported by the approved labels and reviewed by Prakash and Goa in 1999.

The adult literature is a small set of 1990s studies in healthy older people, mostly one to six months long, measuring growth hormone, IGF-1 and body composition surrogates rather than clinical outcomes. Corpas showed twice-daily GHRH (1-29) restored growth hormone and IGF-1 levels in old men, Vittone tested single nightly injections in healthy elderly men, and Khorram gave a long-term course of a sermorelin analogue to age-advanced men and women. These are real studies with a real biochemical endpoint, which is why the tier for raising growth hormone and IGF-1 in older adults is Human trials.

No trial has tested a flat adult dose against placebo for fat loss, strength, sleep or energy. For what modestly raising growth hormone is likely to achieve, the best available proxy is the systematic review of growth hormone itself in the healthy elderly, which found small body composition changes with increased adverse events and no demonstrated functional benefit.

Dose, and why the circulating figure has no trial behind it

The approved regimens are worth knowing because of their structure. Geref for paediatric idiopathic deficiency was 0.03 mg/kg once daily by subcutaneous injection at bedtime. Geref Diagnostic was a single intravenous dose of 1 mcg/kg with timed sampling. Both are weight-based, and the treatment dose was timed to the natural nocturnal growth hormone pulse. Every adult research dose was weight-based or infusion-based too, including a constant intravenous infusion at 25 ng/kg/min for pharmacokinetics and a 14-day continuous subcutaneous infusion of GHRH 1-44.

The fixed microgram amount that compounding pharmacies and wellness clinics supply is convention, not evidence. No trial used a flat adult dose. Of the surrounding conventions, bedtime timing is the most defensible part, because it extrapolates reasonably from growth hormone physiology and from the approved paediatric regimen. Cycling schedules and blended vials are not: no sermorelin study has tested a cycling pattern, and combination vials have no human pharmacokinetic, stability or outcome data as a combination. Combining a GHRH analogue with a ghrelin receptor agonist is pharmacologically synergistic for growth hormone release, which makes the blend more potent rather than safer. The three-way comparison covers that in more detail.

The four-minute problem

Native GHRH (1-29) has a measured disappearance half-time of 4.3 plus or minus 1.4 minutes during constant intravenous infusion in normal men, with metabolic clearance around 40 mL/kg/min. Degradation is largely by dipeptidyl peptidase IV cleavage near one end of the molecule. Adding a D-alanine at position 2, the modification behind “mod GRF 1-29”, lowers clearance to about 21 mL/kg/min and lengthens the half-time only to 6.7 plus or minus 0.5 minutes. Even the stabilized versions are minutes-scale drugs.

So any product claiming that plain sermorelin gives sustained elevated growth hormone for 24 hours is misdescribing its own pharmacology. One injection gives one brief pulse.

Safety, honestly

The dominant reported events in trials and on the former labels were injection site reactions, flushing, headache, dizziness, somnolence and nausea.

The risks that matter are inherited from growth hormone physiology rather than unique to this molecule: fluid retention, peripheral oedema, joint and muscle pain, carpal tunnel syndrome, glucose intolerance and new or worsened diabetes. The modern label for the closely related analogue tesamorelin carries explicit warnings for elevated IGF-1, fluid retention including carpal tunnel, and glucose intolerance, and those should be assumed to apply qualitatively to any GHRH analogue that works.

The unresolved long-term question is IGF-1 and cancer. Higher circulating IGF-1 is associated with increased risk of some cancers, notably prostate and premenopausal breast, in observational meta-regression. That is association rather than demonstrated causation from drug-induced elevation, and no GHRH analogue trial has been long or large enough to test it, which makes the risk plausible, unquantified, and a reason to avoid the class in anyone with active or recent malignancy. See how peptides work in the body for how these signals propagate.

The bottom line

Sermorelin is real pharmacology with a real regulatory history, sold today for an indication that history never covered, at a dose no trial ever used. The diagnostic and paediatric uses were genuinely approved; the adult body composition use is Preclinical only for clinical benefit. As of September 2026 no marketed product exists in the US or Canada, and where adult growth hormone deficiency is genuinely suspected the validated path is proper diagnostic testing followed, if confirmed, by approved replacement under specialist care.

Education only. This page is educational. Most compounds referenced are not approved for human use, and a “research use only” label carries no legal status of its own. Nothing here constitutes medical advice, diagnosis, or treatment.

Sources

Peptides 101Growth HormoneRegulatory
For education only · Not medical advice